Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -2.31% | -53.99% |
Business Summary
Number of employees: 13
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cellular Immunotherapies
100.0
%
| 6 | 100.0 % | 2 | 100.0 % | -75.81% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 2 | 100.0 % | -75.81% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,901,026 | 11,716,439 ( 98.45 %) | 67,746 ( 0.5692 %) | 98.45 % |
Stock B | 0 | 452,000 | 0 | 0 |
Company contact information
Bellicum Pharmaceuticals, Inc.
3730 Kirby Drive Suite 1200
77098, Houston
+281 454 3424
http://www.bellicum.comSector
1st Jan change | Capi. | |
---|---|---|
-53.99% | 822K | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- BPXA Stock
- Company Bellicum Pharmaceuticals, Inc.